CHAPTER 1 INTRODUCTION
1.1. Market Definition
1.2. Executive Summary
1.3. The Scope of the Study
CHAPTER 2 RESEARCH METHODOLOGY
2.1. Secondary Research
2.2. Primary Research
2.3. Analytic Tools and Model
2.4. Economic Indicator
2.4.1. Base Year, Base Currency, Forecasting Period
2.5. Expert Validation
2.6. Study Timeline
CHAPTER 3 MARKET ANALYSIS
3.1. Industry Value Chain Analysis
3.2. Porter's Five Force Analysis
3.2.1. Bargaining Power of Buyers
3.2.2. Bargaining Power of Suppliers
3.2.3. Threats of Substitutes
3.2.4. Threats of New Entrants
3.2.5. Degree of Competition
3.3. PESTLE Analysis
3.3.1. Political
3.3.2. Economical
3.3.3. Social
3.3.4. Technological
3.3.5. Legal
3.3.6. Environmental
3.4. SWOT Analysis
3.4.1. Strengths
3.4.2. Weakness
3.4.3. Opportunities
3.4.4. Threats
3.5. Y-O-Y Analysis
CHAPTER 4 MARKET DYNAMICS
4.1. Market Drivers
4.1.1. Growth in awareness of modern contraception
4.1.2. Cumulative government initiatives and private firms to prevent unwanted abortions and
pregnancies
4.1.3. Growing incidence of sexually transmitted diseases (STDs)
4.1.4. Favourable regulatory scenario and awareness programs
4.1.5. Effective contraception and fewer side effects of IUCDs
4.2. Market Restraints & Challenges
4.2.1. Health risks associated with the use of contraceptive methods
4.2.2. Religious and cultural opposition to contraceptive methods
4.2.3. Lack of awareness and constrained access in developing economies
4.2.4. Availability of alternate contraceptive methods
4.3. Market Opportunities
4.3.1. The rise in disposable income and demand for healthy life
4.3.2. Presence of large unmet contraceptive needs in emerging Asian and African economies
CHAPTER 5 GLOBAL CONTRACEPTIVES MARKET – BY PRODUCT
5.1. Contraceptive Drugs
5.1.1. Oral Contraceptives
5.1.2. Injectable Contraceptives
5.1.3. Topical Contraceptives
5.2. Contraceptive Devices
5.2.1. Condoms
5.2.1.1. Male
5.2.1.2. Female
5.2.2. Diaphragms
5.2.3. Contraceptive Sponges
5.2.4. Vaginal Rings
5.2.5. Subdermal Implants
5.2.6. Intrauterine devices
CHAPTER 6 GLOBAL CONTRACEPTIVES MARKET – BY AGE GROUP
6.1. 15-24
6.2. 25-34
6.3. 35-44
6.4. Above 44
CHAPTER 7 GLOBAL CONTRACEPTIVES MARKET – BY EDUCATION
7.1. Less than high school
7.2. High school graduate
7.3. College graduate
7.4. Others
CHAPTER 8 GLOBAL CONTRACEPTIVES MARKET – BY DISTRIBUTION
CHANNEL
8.1. Hospital Pharmacy
8.1.1. Public
8.1.2. Private
8.2. Independent Pharmacy
8.3. Online Platforms
CHAPTER 9 GLOBAL CONTRACEPTIVES MARKET – BY END USER
9.1. House holds
9.2. Clinics
9.3. Hospitals
CHAPTER 10 GLOBAL CONTRACEPTIVES MARKET - BY GEOGRAPHY
10.1. Introduction
10.2. North America
10.2.1. U.S.
10.2.2. Canada
10.2.3. Mexico
10.2.4. Costa Rica
10.3. South America
10.3.1. Brazil
10.3.2. Argentina
10.3.3. Chile
10.3.4. Columbia
10.3.5. Others
10.4. Europe
10.4.1. U.K.
10.4.2. Germany
10.4.3. France
10.4.4. Italy
10.4.5. Spain
10.4.6. Russia
10.4.7. Netherlands
10.4.8. Switzerland
10.4.9. Poland
10.4.10. Others
10.5. APAC
10.5.1. China
10.5.2. Japan
10.5.3. India
10.5.4. South Korea
10.5.5. Australia & New Zealand
10.5.6. Malaysia
10.5.7. Singapore
10.5.8. Others
10.6. Middle East & Africa
10.6.1. UAE
10.6.2. Saudi Arabia
10.6.3. Iran
10.6.4. Iraq
10.6.5. Qatar
10.6.6. South Africa
10.6.7. Algeria
10.6.8. Morocco
10.6.9. Nigeria
10.6.10. Egypt
10.6.11. Others
CHAPTER 11 GLOBAL CONTRACEPTIVES MARKET - COMPANY PROFILES
11.1. Bayer Healthcare Pharmaceuticals
11.2. Actavis, Inc.
11.3. Cooper Surgical, Inc.
11.4. The Female Health Company
11.5. Merck & Co., Inc.
11.6. Mayer Laboratories, Inc.
11.7. Pfizer, Inc.
11.8. Church & Dwight, Co., Inc.
11.9. Medisafe Distribution Inc.
11.10. Teva Pharmaceutical Industries Limited
11.11. Fuji latex co. ltd
11.12. Johnson & Johnson, Ltd
11.13. Agile Therapeutics
11.14. Ani Pharmaceuticals, Inc.
11.15. Reckitt Benckiser Plc
CHAPTER 12 GLOBAL CONTRACEPTIVES MARKET - COMPETITIVE
LANDSCAPE
12.1. Market Share Analysis
12.2. Strategies adopted by top companies
12.3. Mergers, Acquisitions, Collaborations & Agreements
CHAPTER 13 MARKET INSIGHTS
13.1. Industry Experts Insights
13.2. Analysts Opinions
13.3. Investment Opportunities
CHAPTER 14 APPENDIX
14.1. List of Tables
14.2. List of Figures
